Paralysis: Clinical Trials

50 trials for Paralysis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

50 completed. 50 Phase 1, 14 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 150Completed 50
Phase 214Completed 14

Follow Paralysis: new trials by email Literature Review of Paralysis trials Research Report on Paralysis

Trials (filtered) newest first · largest first

All 50 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Test-retest Study With [18F]PI-2620 in PSP-RS and NDC
[18F]-PI2620 - Progressive Supranuclear Palsy
Phase 1CompletedLife Molecular Imaging GmbH152022-03-102026-10-26
Evaluation of [18F]APN-1607 as a PET Biomarker
[18F] APN-1607 - Progressive Supranuclear Palsy, Healthy Volunteers
Phase 1CompletedInvicro122021-05-252025-02-20
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
antisense oligonucleotide, placebo - Progressive Supranuclear Palsy (PSP)
Phase 1CompletedNovartis Pharmaceuticals592021-02-162025-12-24
Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity
[18F]-PI2620 - Alzheimer Disease, Progressive Supranuclear Palsy
Phase 1CompletedLife Molecular Imaging GmbH102020-11-122026-10-26
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
bepranemab, Placebo - Progressive Supranuclear Palsy
Phase 1CompletedUCB Biopharma SRL252019-12-032023-12-01
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
KL1333, Placebo Oral Tablet - Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies
Phase 1CompletedAbliva AB722019-03-182021-10-20
Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
ABBV-8E12 - Progressive Supranuclear Palsy (PSP)
Phase 1CompletedAbbVie32018-04-172019-12-03
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET
[18F]MNI-958 - Healthy Volunteers, Alzheimer Disease
Phase 1CompletedInvicro162018-03-122020-02-17
Adipose Stem Cells for Traumatic Spinal Cord Injury
Autologous, Adipose derived Mesenchymal Stem Cells - Spinal Cord Injuries, Paralysis
Phase 1CompletedMohamad Bydon102017-12-052022-08-30
RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease
RQ-00000010, Placebo - Parkinson's Disease, Gastroparesis
Phase 1CompletedVirginia Commonwealth University512016-06-012019-10-09
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
BIIB092, Placebo - Progressive Supranuclear Palsy
Phase 1CompletedBiogen482015-10-022018-09-04
Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
Single dose C2N-8E12, Single dose placebo - Progressive Supranuclear Palsy
Phase 1CompletedC2N Diagnostics322015-07-012017-07-26
Young Plasma Transfusions for Progressive Supranuclear Palsy
Fresh Frozen Plasma - Progressive Supranuclear Palsy
Phase 1CompletedUniversity of California, San Francisco62015-05-012020-08-11
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
Salsalate - Progressive Supranuclear Palsy
Phase 1CompletedAdam Boxer102015-04-012021-04-01
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
AST-OPC1 - Cervical Spinal Cord Injury, Spine Injury
Phase 1 / Phase 2CompletedLineage Cell Therapeutics, Inc.252015-03-012021-07-14
The Safety of ahSC in Chronic SCI With Rehabilitation
Autologous human Schwann cells - Spinal Cord Injury, Paraplegia
Phase 1CompletedW. Dalton Dietrich82015-01-012019-08-14
Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
Flortaucipir F18, Brain PET scan - Progressive Supranuclear Palsy, Corticobasal Degeneration
Phase 1CompletedAvid Radiopharmaceuticals292014-08-122020-08-28
Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects
Nizatidine, Lisinopril, Placebo - Gastroparesis
Phase 1CompletedAdil Bharucha242014-07-012015-04-30
Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis
TC-6499, Placebo - Gastroparesis
Phase 1 / Phase 2CompletedTargacept Inc.802014-06-012015-05-12
Safety Study of TPI-287 to Treat CBS and PSP
TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo - Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS)
Phase 1CompletedUniversity of California, San Francisco442014-05-012020-04-15

Showing 20 of 50. Sign in to see all of them.

Narrower conditions

Supranuclear Palsy, Progressive (17)  ·  Gastroparesis (15)  ·  Quadriplegia (8)  ·  Spinal Cord Injuries (8)  ·  Paraplegia (6)  ·  Stroke (6)  ·  Hemiplegia (5)  ·  Corticobasal Degeneration (4)  ·  Alzheimer Disease (3)  ·  Paresis (3)  ·  Pick Disease of the Brain (3)  ·  Diabetes Mellitus (2)  ·  Nausea (2)  ·  Parkinson Disease (2)

Broader conditions

Pathological Conditions, Signs and Symptoms (50)  ·  Signs and Symptoms (50)  ·  Neurologic Manifestations (49)  ·  Nervous System Diseases (36)  ·  Central Nervous System Diseases (33)  ·  Brain Diseases (25)  ·  Cranial Nerve Diseases (19)  ·  Basal Ganglia Diseases (18)  ·  Eye Diseases (18)  ·  Movement Disorders (18)  ·  Neurodegenerative Diseases (18)  ·  Ocular Motility Disorders (18)  ·  Ophthalmoplegia (18)  ·  Digestive System Diseases (15)

Interventions

N-(3-fluorophenyl)-1-((4-(((3S)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine (3)  ·  ((18)F)PI-2620 (2)  ·  7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (2)  ·  Constraint Induced Movement Therapy (2)  ·  florbetapir (2)  ·  Acetylcarnitine (1)  ·  Acupuncture Therapy (1)  ·  Body Piercing (1)  ·  Buspirone (1)  ·  Glucose (1)  ·  Ketoconazole (1)  ·  Levodopa (1)  ·  Lisinopril (1)  ·  Lithium (1)  ·  Melatonin (1)

Sponsors

GlaxoSmithKline (5)  ·  University of California, San Francisco (3)  ·  Invicro (2)  ·  Life Molecular Imaging GmbH (2)  ·  W. Dalton Dietrich (2)  ·  AbbVie (1)  ·  Abliva AB (1)  ·  Adam Boxer (1)  ·  Adil Bharucha (1)  ·  Avid Radiopharmaceuticals (1)  ·  Biogen (1)  ·  C2N Diagnostics (1)  ·  Dr. Gabriel Zeilig (1)  ·  Forest Laboratories (1)  ·  Georgia Institute of Technology (1)

Countries

United States (34)  ·  United Kingdom (6)  ·  Germany (4)  ·  Australia (3)  ·  Canada (3)  ·  Belgium (2)  ·  Spain (2)  ·  Denmark (1)  ·  Israel (1)  ·  Norway (1)  ·  Singapore (1)  ·  Sweden (1)

Top investigators

Adam Boxer, MD, PhD (3)  ·  Allan Levi, MD, PhD (2)  ·  Andrew Stephens, MD, PhD (2)  ·  James Guest, MD, PhD (2)  ·  Adam L. Boxer, M.D., Ph.D. (1)  ·  Adil Bharucha, MBBS, MD (1)  ·  Beatrice J Kiratli, PhD (1)  ·  Chua Karen, MD (1)  ·  Claire Henchcliffe, MD DPhil (1)  ·  Dalton Dietrich, PhD (1)  ·  Danna Jennings, MD (1)  ·  David Russell, M.D., Ph. D (1)

Results publications

PMID 19615045, PMID 19666345, PMID 19965145, PMID 21381984, PMID 21575185, PMID 21652288, PMID 22254998, PMID 22275632, PMID 22531737, PMID 22692932, PMID 22738299, PMID 22961573, PMID 23366834, PMID 23366943, PMID 23639598, PMID 23844986, PMID 24119615, PMID 24284925, PMID 25148846, PMID 25570772, PMID 26084322, PMID 28225648, PMID 28782145, PMID 29760737, PMID 31122495, PMID 31710340, PMID 31785831, PMID 32493977, PMID 35364569, PMID 35901693, PMID 36772802, PMID 38561341, PMID 41389437

NIH funding

1RC1EB010915-01 (1), 2019 (1), K01HD069504 (1), P01DK068055 (1), R43AT004489 (1), UL1RR024150 (1)